CPT1A and prostate carcinoma: In prostate, increased beta-oxidation has been shown to promote prostate cancer cell survival49 while inhibition of lipid catabolism, achieved via pharmacological inhibition or CPT1a silencing, decreased tumour growth and restored enzalutamide sensitivity50,51.